Evidence map›Paper›PMID 33261213›Full record

ReviewJournal of fungi (Basel, Switzerland)2020

Amphotericin B and Other Polyenes-Discovery, Clinical Use, Mode of Action and Drug Resistance.

Hans Carolus, Siebe Pierson, Katrien Lagrou, Patrick Van Dijck

Abstract readReview
In one paragraph

Review in Journal of fungi (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 170 papers.

0numbers the graph read from it
0cells of the map it votes in
170citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

170 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Micafungin exposure drives multidrug resistance inbioRxiv : the preprint server for biology · 2026
    Article
  9. Amphotericin B Resistance inbioRxiv : the preprint server for biology · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Antimicrobial 3D printed implants for periprosthetic joint infections.Drug delivery and translational research · 2026
    Article
  17. Targeting the polyene chain represents an adjuvant strategy for optimizing polyene antifungals.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  18. Deciphering the multidrug resistance paradigm inAntimicrobial agents and chemotherapy · 2026
    Review
  19. A review of the current anti-New microbes and new infections · 2026
    Review
  20. Microbiology and molecular biology reviews : MMBR · 2026
    Review

110 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hans CarolusVIB-KU Leuven Center for Microbiology, 3001 Leuven, Belgium.ORCID 0000-0003-1507-3475
Siebe PiersonVIB-KU Leuven Center for Microbiology, 3001 Leuven, Belgium.
Katrien LagrouLaboratory of Clinical Bacteriology and Mycology, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3001 Leuven, Belgium.
Patrick Van DijckVIB-KU Leuven Center for Microbiology, 3001 Leuven, Belgium.

Funding

Fonds Wetenschappelijk Onderzoek 11D7620N
6 · The paper itself

Abstract

Although polyenes were the first broad spectrum antifungal drugs on the market, after 70 years they are still the gold standard to treat a variety of fungal infections. Polyenes such as amphotericin B have a controversial image. They are the antifungal drug class with the broadest spectrum, resistance development is still relatively rare and fungicidal properties are extensive. Yet, they come with a significant host toxicity that limits their use. Relatively recently, the mode of action of polyenes has been revised, new mechanisms of drug resistance were discovered and emergent polyene resistant species such as

Indexed as

amphotericin Bantifungal drug resistancediscoverymode of actionpolyene

Identifiers

PMID33261213
PMCPMC7724567

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.